Description
SWOT ANALYSIS OF ACTELION
Actelion
Parent Company
Actelion
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Together we innovate
USP
Actelion operates in niche segment of orphan diseases
STP
Segment
Orphan diseases such as digital ulcers, gaucher’s disease
Target Group
Healthcare professionals operating in these areas
Actelion is company which blends biotechnological innovation with Positioning pharmaceutical discipline
SWOT Analysis
1. Actelion operates in niche segment of orphan diseases which have less competition 2. Strong presence in over 60 plus markets 3. Key drugs in the late stages of development in pipeline 4. Longer patent life of key drugs Strength 5. Over 2500+ well trained employees
1. Limited presence in emerging markets Weakness 2. They have only four blockbuster drugs
1. Diversify portfolio in specialty diseases 2. Contract manufacturing of G.P diseases Opportunity 3. Market introduction of Cadazolid
1. Increasing pressure to reduce prices in Europe 2. Growing number of generic drugs Threats 3. Global economic slowdown
Competition
1. Abbott laboratories 2. Amicus therapeutics Inc 3. Aradigm corporation Competitors 4. AstraZeneca
doc_432440912.docx
SWOT ANALYSIS OF ACTELION
Actelion
Parent Company
Actelion
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Together we innovate
USP
Actelion operates in niche segment of orphan diseases
STP
Segment
Orphan diseases such as digital ulcers, gaucher’s disease
Target Group
Healthcare professionals operating in these areas
Actelion is company which blends biotechnological innovation with Positioning pharmaceutical discipline
SWOT Analysis
1. Actelion operates in niche segment of orphan diseases which have less competition 2. Strong presence in over 60 plus markets 3. Key drugs in the late stages of development in pipeline 4. Longer patent life of key drugs Strength 5. Over 2500+ well trained employees
1. Limited presence in emerging markets Weakness 2. They have only four blockbuster drugs
1. Diversify portfolio in specialty diseases 2. Contract manufacturing of G.P diseases Opportunity 3. Market introduction of Cadazolid
1. Increasing pressure to reduce prices in Europe 2. Growing number of generic drugs Threats 3. Global economic slowdown
Competition
1. Abbott laboratories 2. Amicus therapeutics Inc 3. Aradigm corporation Competitors 4. AstraZeneca
doc_432440912.docx